Who We Are

For over a decade, Retina Labs has been a leader in teleretinal screening for diabetic retinopathy and other ocular disorders.  Our cloud-based iVision teleophthalmology platform offers an integrated solution that combines advanced ocular imaging, clinical interpretation and reporting tools with electronic referrals. Our solutions allow healthcare providers to improve access to quality eye care while streamlining the processes related to the management of chronic eye diseases such as diabetic retinopathy, glaucoma, age-related macular degeneration and retinopathy of prematurity. iVision is the teleophthalmology platform of choice for health systems, primary care providers and health plan looking to close care gaps around diabetic eye disease, improve outcomes and reduce costs.

We believe that telemedicine can play a crucial role in improving access to eye care and in preventing unnecessary vision loss. This approach allows diabetic patients to get their annual retinal exam performed closer to home minimizing travel time—especially for remote communities, as well as improved convenience for those with mobility issues. Retina Labs teleretinal screening solutions and services have proven to generate significant measurable cost savings while improving patient experience and outcomes.

Our Story

In the beginning, we set out to fundamentally change the way in which retinal screenings were conducted through innovative telemedicine technology and clinical assessment tools. Retina Labs was one of the very first software companies to develop a completely web-based telemedicine platform specifically designed for diabetic retinopathy screening.

Diabetes is a growing global epidemic. Each year, millions of diabetics go blind or suffer from unnecessary vision loss as a result of diabetic retinopathy, a common complication of diabetes. While diabetic retinopathy has become the leading cause of blindness, 95% of cases are preventable and treatable if detected early enough through an annual retinal exam.

However, only half of patients with diabetes are being screened for diabetic retinopathy. For many, the disease goes undetected until it’s too late as patients are unaware they even have the condition. For payers and health systems, the cost of treating diabetic retinopathy is significantly higher than any investments in prevention and early detection of the disease. For patients, the impact of vision impairment represents fundamental diminution of the quality of life.

Richard Pridham
President & CEO

Prior to joining Retina Labs as President & CEO and investor, Richard acquired over 25 years of senior management and entrepreneurial experience in the software, technology and healthcare industries. During that time Richard led and grew multiple companies with several successful exits. At Retina Labs, Richard is responsible for business strategy, marketing and sales. Since joining in 2016, Richard has led Retina Labs to its position as a leading provider of teleophthalmology solutions. Richard is a graduate of McGill University.

Hamid Fotuhi
Vice President of Technology & Product

Hamid is a co-founder of Retina Labs. As such, he has held a pivotal role in the design and development of the company’s solutions. In his current role as Vice President of Technology and Product, he oversees all IT operations, application development, customer deployments, training and technical support Prior to Retina Labs, Hamid acquired years of professional experience in the technology and software sector across multiple industries. Hamid holds a BSc in Applied Mathematics and Computer Science from Concordia University.

Our Vision & Mission

Vision:

To eliminate preventable blindness.

Mission:

To reduce vision loss through improved accessibility to retinal screenings for early detection and treatment of eye diseases such as such as diabetic retinopathy, age-related macular degeneration and glaucoma as well as retinopathy of prematurity.

Pioneers in Teleophthalmology

iVision is proudly recognized by the World Health Organization as a break-through innovation in healthcare. For over a decade, Retina Labs has been the proven innovator and market leader in cloud-based teleophthalmology. Unmatched within the industry, the iVision teleophthalmology suite meets the highest medical standards.

News & Events

Montreal Technoparc

Retina Labs Relocates Canadian Office to Montreal Technoparc

Retina Labs is pleased to announce that it has moved its Canadian offices to the Montreal Technoparc. The Techoparc is Canada’s most prestigious science park and serves as an innovation and research hub for over 90 established and emerging companies in the medtech, software, life science, telecommunications and aerospace industries.

AHIP 2019

Retina Labs to Sponsor & Exhibit at AHIP 2019

Retina Labs is pleased to announce that it will sponsor exhibit at the upcoming America’s Health Insurance Plans (AHIP) Institute and Expo to be held in Nashville, TN June 19th to 21st, 2019. Known as the Essential Event for the Health Care Industry, AHIP’s Institute & Expo consistently delivers results for hundreds of solutions providers.

Retina Labs Recognized as Innovator and Disruptor in Eye Healthcare

Retina Labs is excited to be one of a select group of companies mentioned in this report. Appearing in the category of Telemedicine / Telerefraction, Retina Labs has emerged a leader in the area of ocular telehealth.

Be A Part of Our Team

We are always looking for talented people to join our team and help fuel our growth.

Office Locations

Canada

7140 Albert-Einstein, Suite 220
Montreal, Quebec, H4S 2C1
Phone: (514) 344-2692
Toll Free: (866) 344-2692
Montreal

Business Hours

Monday – Friday 9am-5pm EST

United States

One Liberty Plaza
165 Broadway, Suite 2301
New York, New York, 10006
Toll Free: (866) 344-2692
Montreal

Business Hours

Monday – Friday 9am-5pm EST